Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

Infographic showing that more than half of every dollar spent on brand name medicines goes to PBMs

New study: Entities that don’t make medicines get half of what is spent on those medicines

Elizabeth Carpenter
Half of every dollar spent on brand medicines goes to entities that play no role in the research, development, or manufacturing of those medicines, according to a new analysis by Berkeley Research Group (BRG).
Chemist studying a pipette and test tube intently

40 Years of Hatch-Waxman: How Can We Secure its Legacy?

Jocelyn Ulrich
Jocelyn Ulrich
Today, the Drug Price Competition and Patent Restoration Act - better known as the Hatch-Waxman Act - celebrates its 40th anniversary, marking four decades of success in fueling biopharmaceutical innovation while growing the U.S. generic market into the powerhouse it is today.

PhRMA urges HRSA not to impede new 340B pricing approaches to improve transparency and integrity

Drew Voytal
It’s past time to get 340B back on track and working for patients.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.